Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT03140176 | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving…(OPTIMISE) | — | terminated | May 4, 2017 | Pfizer | The study was terminated early due to the inability to recruit the planned number of patients | Enrollment / accrual |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | Phase 2 | withdrawn | Jan 30, 2017 | M.D. Anderson Cancer Center | PI's Request | Other (stated, no rule matched) |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04684628 | 68Ga-PSMA PET/CT in Prostate Cancer | Phase 3 | suspended | Dec 24, 2020 | University of Saskatchewan | Study is suspended due to some logistic issues | Other (stated, no rule matched) |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP… | Phase 1 | withdrawn | Apr 11, 2023 | National Cancer Institute (NCI) | No subjects enrolled in the study | Enrollment / accrual |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial… | Phase 2 | withdrawn | Sep 21, 2023 | Genmab | Enrollment challenged by availability of other treatment options | Enrollment / accrual |
| NCT04927559 | Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing… | — | terminated | Jun 16, 2021 | University of Southern California | Low accrual | Enrollment / accrual |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell… | Phase 1 | terminated | Jun 12, 2020 | Abramson Cancer Center at Penn Medicine | failure to accrue | Enrollment / accrual |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or… | Phase 2 | terminated | Apr 22, 2024 | Fundacion Oncosur | The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive… | Other (stated, no rule matched) |
| NCT03915405 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Phase 1 | terminated | Apr 16, 2019 | Kyowa Kirin, Inc. | Termination was based on the business decision | Sponsor / business decision |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | Phase 1 / Phase 2 | terminated | Jul 7, 2020 | Institute of Cancer Research, United Kingdom | Funder decided that response outcomes to date did not support continuation of the study. | Other (stated, no rule matched) |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of… | Phase 1 | withdrawn | Sep 9, 2020 | University of Alabama at Birmingham | No recruitment/enrollment and funding expired. | Enrollment / accrual |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma… | Phase 1 / Phase 2 | terminated | Sep 14, 2022 | Avenge Bio, Inc | Sponsor Decision to close study | Sponsor / business decision |
| NCT05699135 | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People… | — | terminated | Jan 26, 2023 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a… | Phase 3 | withdrawn | Mar 8, 2024 | Second Xiangya Hospital of Central South University | The standard measures of anaesthesia in cystoscopy are not uniform internationally, and given this,… | Enrollment / accrual |
| NCT04633148 | Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients… | Phase 1 | terminated | Nov 18, 2020 | AvenCell Europe GmbH | Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded… | Other (stated, no rule matched) |
| NCT01393119 | Phase II, Dose Finding Study of GTx-758 | Phase 2 | terminated | Jul 13, 2011 | GTx | FDA Clinical Hold | Other (stated, no rule matched) |
| NCT03128294 | Long Term Survivors in Ovarian Cancer | — | terminated | Apr 25, 2017 | University Medical Center Groningen | Data was not sufficiently complete and reliable for analysis (retrospective chart research) | Other (stated, no rule matched) |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial… | — | terminated | May 26, 2023 | Wake Forest University Health Sciences | This was a national survey of physicians. Per the protocol, they were only allowed to be contacted… | Other (stated, no rule matched) |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT04806334 | Radiogenomics of Muscle Invasive Bladder Cancer | N/A | terminated | Mar 19, 2021 | Cedars-Sinai Medical Center | Slow accrual | Enrollment / accrual |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | N/A | terminated | Feb 1, 2021 | Milton S. Hershey Medical Center | Difficulty enrolling and we lost exercise specialist | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in… | Phase 1 | withdrawn | Jun 8, 2023 | Weill Medical College of Cornell University | Insufficient funding | Funding |
| NCT04677855 | Study of PCUR-101 in Combination With ADT in Patients With mCRPC | Phase 1 | terminated | Dec 21, 2020 | Pellficure Pharmaceuticals, Inc | Business Decision due to insufficient enrollment | Enrollment / accrual |
| NCT03810105 | A Study of Olaparib and Durvalumab in Prostate Cancer | Phase 2 | terminated | Jan 18, 2019 | Memorial Sloan Kettering Cancer Center | Due to low accrual | Enrollment / accrual |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT06355843 | Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of… | N/A | suspended | Apr 9, 2024 | The First Affiliated Hospital of Anhui Medical University | The 68Ge/68Ga generator is currently at the end of its lifespan. We are trying to purchase new… | Other (stated, no rule matched) |
| NCT05390021 | PET/MRI in Endometrial Cancer | N/A | withdrawn | May 25, 2022 | Massachusetts General Hospital | Unable to enroll patients to study | Enrollment / accrual |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for… | Phase 2 | withdrawn | Jul 6, 2022 | National Cancer Institute (NCI) | Closed by study team, no subjects enrolled. | Enrollment / accrual |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage… | Phase 2 | terminated | Feb 8, 2021 | Henry Ford Health System | Low accrual | Enrollment / accrual |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in… | Phase 2 | withdrawn | Sep 2, 2021 | Agenus Inc. | Study was never initiated. | Other (stated, no rule matched) |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | Phase 1 / Phase 2 | terminated | Apr 29, 2009 | University Health Network, Toronto | Poor recruitment | Enrollment / accrual |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or… | Phase 1 / Phase 2 | terminated | Oct 16, 2013 | Fox Chase Cancer Center | Study drug is no longer supplied by grantor. | Other (stated, no rule matched) |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | Phase 2 | withdrawn | Jan 28, 2020 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With… | Phase 1 | terminated | Oct 14, 2020 | Haihe Biopharma Co., Ltd. | Business decision | Sponsor / business decision |
| NCT02782715 | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | May 25, 2016 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT03657108 | CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation | N/A | terminated | Sep 4, 2018 | Icahn School of Medicine at Mount Sinai | Decision made by DSMB to terminate study in April 2023. | Other (stated, no rule matched) |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | N/A | withdrawn | Apr 10, 2019 | University Health Network, Toronto | This study is being closed. The protocol may be reviewed and consolidated under a new study… | Other (stated, no rule matched) |
| NCT02574442 | Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer(Confocal) | — | terminated | Oct 12, 2015 | British Columbia Cancer Agency | Funding has run out | Funding |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | — | terminated | Sep 18, 2017 | British Columbia Cancer Agency | No funding | Funding |
| NCT05361915 | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration… | Phase 2 | suspended | May 5, 2022 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men… | Phase 2 | withdrawn | Oct 10, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Principal Investigator has decided not to activate this trial. | Investigator |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to… | Phase 1 | terminated | May 20, 2020 | Mersana Therapeutics | discontinued development program | Other (stated, no rule matched) |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | Phase 1 | terminated | Jan 31, 2022 | Lioe-Fee de Geus-Oei, MD PhD | Reached the stop criteria after the interim analysis | Efficacy / futility |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal… | Phase 2 | terminated | Oct 14, 2016 | Swiss Cancer Institute | Decision Board no further financial support after 3 years of follow-up as remaining patients in… | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 14, 2024source: clinicaltrials